Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20170708 | 0.83 | OPRM1 (0.42) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL12944957 | 0.83 | OPRM1 (0.42) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL20170873 | 0.73 | OPRD1 (0.39) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL10222587 | 0.71 | GAA (0.39) | OPRD1DRD2DRD4DRD3 | |
| SCHEMBL20170597 | 0.70 | OPRD1 (0.43) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL12944958 | 0.70 | OPRD1 (0.43) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL12944959 | 0.68 | OPRM1 (0.39) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL12960900 | 0.68 | OPRM1 (0.59) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL20170700 | 0.68 | OPRM1 (0.59) | OPRM1OPRD1SIGMAR1OPRK1 | |
| SCHEMBL12646223 | 0.68 | OPRM1 (0.59) | OPRM1OPRD1SIGMAR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453895-B1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-23 | — | — | EP | disclosed |